Targeting the P2X7 receptor reduces harmful human brain inflammation
Researchers found that blocking the P2X7 receptor lowers inflammation in human brain tissue, offering a potential path to repurpose existing drugs for neurological conditions.
FTMQ Science, written by our newsroom1 view

Blocking a specific receptor known as P2X7 significantly reduced inflammation in human brain tissue, ScienceDaily reported. The research was published in the journal Brain and was led by Professor Nicholas Barnes at the University of Birmingham. Scientists identified the mechanism as a potential new treatment strategy for several neurological and psychiatric disorders. [1]
The findings indicate that researchers may be able to repurpose existing drugs that already block the P2X7 receptor. ScienceDaily reported that targeting this receptor could help treat conditions such as Alzheimer's disease, Parkinson's disease, traumatic brain injury, depression, and schizophrenia. [1]
Alzheimer's disease is a neurodegenerative disorder that serves as the most common cause of dementia, accounting for 60 to 70 percent of cases. Early symptoms typically involve difficulty remembering recent events, followed by language problems, mood changes, and bodily decline. [3]
Parkinson's disease is a neurodegenerative disorder of the central nervous system that affects both motor and non-motor systems. Symptoms develop gradually and include tremors, rigidity, slowness of movement, balance difficulties, and cognitive changes. [4]
In short
- Blocking the P2X7 receptor significantly reduced inflammation in human brain tissue.
- Professor Nicholas Barnes led the study published in the journal Brain.
- existing drugs that block P2X7 could be repurposed to treat Alzheimer's and Parkinson's disease.
- Alzheimer's disease accounts for 60 to 70 percent of dementia cases.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Drug target could block brain inflammation linked to Alzheimer’s and Parkinson’sScienceDaily Mind & Brain, 46d ago (the report this story comes from)
- [2]Biomedicine | China steps up Alzheimer’s, Parkinson’s drug push, looks to TCMSouth China Morning Post, 47d ago
Background
- [3]Alzheimer's disease on Wikipedia
- [4]Parkinson's disease on Wikipedia
Our newsroom writes these reports with the help of software, from the 4 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Science
Earlier reports of ours on the same people and subjects.
- Blocking immune cells protects mouse brains from tau disease damageBody & Mind, 32d ago
- Semaglutide repairs damaged blood vessels in chronic kidney disease patientsTop Stories, 12d ago
- Gene variant APOE4 linked to blood vessel scarring in Alzheimer studyTop Stories, 40d ago
- Alzheimer's mutations disrupt nerve muscle connections outside the brainNew Research, 11d ago
- UCLA study links agricultural pesticide exposure to elevated Parkinson's disease riskNew Research, 20d ago
More in Body & Mind
- Researchers combine focused ultrasound and microRNAs to combat glioblastoma20d ago
- International study finds blood test predicts early Alzheimer risk21d ago
- Chronic back pain engages brain network linked to self identity22d ago
- Prefrontal brain activity fails to predict individual emotion regulation ability23d ago
- Psychological traits determine how people remember physical affection23d ago
- Mayo Clinic researchers identify new strategies to target cellular senescence25d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.